Biomedical Engineering Reference
In-Depth Information
gushi. Clinical response in japanese metastatic melanoma patients treatted with
peptide cocktail-pulsed dendritic cells. Journail of Translational Medicine 3: 4-14,
(2005).
[8] A. Murshid, J. Gong, and S. K. Calderwood. Heat-shock proteins in cancer vaccines:
agents of antigen cross presentation. Expert Rev Vaccines 7: 1019-1030, (2008).
[9] D. R. Ciocca and S. K. Calderwood. Heat shock proteins in cancer: diagnostic, prog‐
nostic, predictive, and treatment implications. Cell Stress & Chaperones 10: 263-270,
(2005)
[10] J. Kaiser. A detailed genetic portrait of the deadliest human cancers. Science 321:
1280-1281, (2008).
[11] C. V. Nicchitta, D. M. Carrick, and J. C. Baker-LePain. The messenger and the mes‐
sage: gp96 (grp94)-peptide interactions in cellular immunity. Cell Stress & Chaper‐
ones 9 : 325-331, (2004).
[12] M. Romanucci, A. Marinelli, S. Giuseppe, and L. Della Salda. Heat shock protein ex‐
pression in canine malignant mammary tumours. BMC Cancer 6: 171-183, (2006).
[13] M. Heughebaert, R.Z. LeGeros, M. Gineste ,A. Guilhem, G. Bonel, Physico chemical
characterization of deposits associated with HA-ceramics implanted in osseous sites.
J Biomed Mater Res. 22(3 Suppl): 257-68 (1988)
[14] P. Frayssinet, A. Guilhem, Cell transfection using HA-ceramics. Bioprocessing Jour‐
nal, 3, 4 (2004)
[15] W. Zou. Immunosuppressive networks in the tumour environment and their thera‐
peutic relevance. Nature Reviews 5: 263-274, (2005).
[16] L. M. Liau, R. M. Prins, S. M. Kiertscher, S. K. Odesa, T. J. Kremen, A. J. Giovannone,
J.-W. Li, D. J. Chute, P. S. Mischel, T. F. Cloughesy, and M. D. Roth. Dendritic cell
vaccination in glioblastoma patients induces systemic and intracranial T-cell respons‐
es modulated by the local central nervous system tumor microenvironment. Clinical
Cancer Research 11: 5515-5525, (2005).
[17] G. P. Dunn, I. F. Dunn, and T. W. Curry. Focus on TILs: prognostic significance of
tumor infiltrating lymphocytes in human glioma. Cancer Immunity 7: 12-27, (2007).
[18] K. Miller, M. Wang , J. Gralow, M. Dickler, M. Cobleigh, E.A. Perez, T. Shenkier, D.
Cella, N.E. Davidson: Paclitaxel plus bevacizumab versus paclitaxel alone for meta‐
static breast cancer. N Engl J Med , 357: 2666-2676, (2007).
[19] N. Ferrara, K. J. Hillan, H.-P. Gerber, W. Novotny. Discovery and development of
bevacizumab, an anti-VEGF antibody for treating cancer. Nature Reviews Drug Dis‐
covery, 3: 391-400, (2004)
Search WWH ::
Custom Search